Syros Pharmaceuticals Inc. buy stratec
Start price
02.12.18
/
50%
€68.82
Target price
04.11.21
€130.00
Performance (%)
-43.91%
End price
05.11.21
€38.60
Summary
This prediction ended on 05.11.21 with a price of €38.60. Massive losses of -43.91% were the result for the BUY prediction by stratec. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Syros Pharmaceuticals Inc. | 1.702% | 1.702% | 75.735% | -90.440% |
| iShares Core DAX® | -0.922% | -1.993% | 13.399% | 16.075% |
| iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% | 46.938% |
| iShares Nikkei 225® | 2.224% | -5.187% | 20.497% | 4.643% |
| iShares S&P 500 | -0.026% | -0.918% | 30.410% | 42.418% |
Comments by stratec for this prediction
In the thread Syros Pharmaceuticals Inc diskutieren
Syros with an enriched pipeline of molecules to potentially service immuno-oncology indications.
Oppenheimer starts Syros Pharmaceuticals with a new Outperform rating and $13 price target. Oppenheimer's analyst 'believes the company's lead program, SY-1425, has demonstrated compelling
clinical proof-of-concept in a biomarker-defined population of acute myeloid leukemia patients and has an opportunity for approval in multiple therapeutic settings. However, recent changes in the AML
competitive landscape, such as the approval of venetoclax, could limit uptake and prolong development timelines relative to previous estimates.' Nonetheless, the analyst 'sees SY-1425 + azacitidine as a promising combination therapy in AML and expects the company to announce updated development plans in early 2019.'
Kursziel geändert auf 13,0
In the thread Trading Syros Pharmaceuticals Inc
Die von stratec gewählte maximale Laufzeit wurde überschritten
Stopped prediction by stratec for Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€89.93
08.01.18
08.01.18
€252.56
03.12.18
03.12.18
-23.47%
03.12.18
03.12.18
